title: Association of HIV-1 viral phenotype in the MT-2 assay with perinatal HIV transmission.
abstract: A case-control design study was used to investigate the association of maternal HIV-1 phenotype in MT-2 cells at or near the time of delivery with perinatal transmission of HIV-1, controlling for maternal CD4 percentage and duration of rupture of membranes, in 48 transmitting and 96 non-transmitting HIV-1-infected mothers who gave birth between 1990 and 1995. The non-syncytium-inducing (NSI) phenotype was more commonly seen in transmitting mothers compared with non-transmitting mothers (90% vs. 75%, p =.04). In a multivariable logistic regression model, the following maternal characteristics were significantly associated with HIV transmission: NSI phenotype (odds ratio [OR] = 6.08; 95% confidence interval [CI]: 1.73-21.35) and log(10) viral load (OR = 2.11; CI: 1.19-3.74). Finally, the association of NSI phenotype with transmission was stronger in transmitting women who received azidothymidine during pregnancy compared with transmitters who did not.
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, Columbia University, New York, New York 10032, USA. psL1@columbia.edu
authors.forename: Philip
authors.initials: P
authors.lastname: LaRussa
authors.forename: Laurence S
authors.initials: LS
authors.lastname: Magder
authors.forename: Jane
authors.initials: J
authors.lastname: Pitt
authors.forename: Anne
authors.initials: A
authors.lastname: Sill
authors.forename: George
authors.initials: G
authors.lastname: Hillyer
authors.forename: F Blaine
authors.initials: FB
authors.lastname: Hollinger
authors.forename: Judy
authors.initials: J
authors.lastname: Lew
authors.forename: Kenneth
authors.initials: K
authors.lastname: McIntosh
authors.forename: Joseph
authors.initials: J
authors.lastname: Kufera
authors.forename: Jim
authors.initials: J
authors.lastname: Bremer
authors.forename: William
authors.initials: W
authors.lastname: Blattner
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002460:Cell Line; D005260:Female; D015726:Giant Cells / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission* / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D015999:Multivariate Analysis; D010641:Phenotype; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology*; D012044:Regression Analysis; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine